Can remarkable science be turned into mass-market products, asks David Crow. Cell therapies to treat blood cancers offer hope to patients who have exhausted all other possibilities and are likely to get regulatory approval this year. But they are expensive and production is time consuming, says David. The process needs to be streamlined and capacity matched to demand

Copyright The Financial Times Limited 2018. All rights reserved.

Comments have not been enabled for this podcast.